Minimally oxidized LDL induces TLR4-dependent lipoprotein uptake by macrophages
Minimally oxidized LDL induces TLR4-dependent lipoprotein uptake by macrophages. Polyoxygenated CE hydroperoxides, with a generic structure shown in the top-center portion of the Figure (n = 1 – 4), are responsible for cytoskeletal rearrangements induced by mmLDL in macrophages. The TLR4/MD-2 receptor complex is required for the cytoskeletal effects of mmLDL and OxCE. The TLR4-dependent signaling pathway involves recruitment of Syk, likely via the Syk N-terminal SH2 domain binding to a phospho-tyrosine in the C-terminal domain of TLR4, phosphorylation of Syk, with subsequent activation of Vav1, Ras, Raf, MEK1 and ERK1/2. Downstream from ERK1/2, Cdc42, Rac and paxillin are activated, inducing actin polymerization and robust plasma membrane ruffling as shown in the bottom-left image (green, F-actin; blue, nucleus). In addition, ERK1/2 mediates Rho activation, and mmLDL activates PI3K (in a TLR4-independent manner); both Rho and PI3K regulate ruffles closure into large endosomes. In the process of such a liquid phase uptake occurring in lipoprotein-rich environments, large quantities of lipoproteins become captured, including mmLDL and also native LDL and OxLDL. The result is the formation of lipid-laden macrophage foam cells, as the one shown in the bottom-right image (red, Oil Red O staining of intracellular neutral lipid). Note that this mechanism combines a specific receptor (TLR4) recognition of distinct oxidized lipid moieties in mmLDL and the non-specific macropinocytic uptake of a variety of lipoproteins present in the vicinity of a macrophage.

Publication
Toll-like Receptor-4 and Lipoprotein Accumulation in Macrophages. () Yury I. Miller, et al. Trends Cardiovasc Med. ;19(7):227-232. Figure: F1.Organism | Group | Word | Match | Source | NCBI Symbol | NCBI ID |
---|---|---|---|---|---|---|
Homo sapiens | Primates | MD-2 | MD-2 | ncbigene_synonym | LY96 | 23643 |
Homo sapiens | Primates | TLR4 | TLR4 | ncbigene_symbol | TLR4 | 7099 |
Homo sapiens | Primates | CD14/MD-2/TLR4 | CD14 | ncbigene_symbol | CD14 | 929 |
Homo sapiens | Primates | CD14/MD-2/TLR4 | CD14 | ncbigene_synonym | NDUFA2 | 4695 |
Homo sapiens | Primates | GTP | GTP | ncbigene_synonym | MTG1 | 92170 |
Homo sapiens | Primates | Raf | RAF | ncbigene_synonym | ZHX2 | 22882 |
Homo sapiens | Primates | Raf | RAF | famplex_relations | ARAF | 369 |
Homo sapiens | Primates | Raf | RAF | famplex_relations | BRAF | 673 |
Homo sapiens | Primates | Raf | RAF | famplex_relations | RAF1 | 5894 |
Homo sapiens | Primates | Ras | RAS | famplex_relations | KRAS | 3845 |
Homo sapiens | Primates | Ras | RAS | famplex_relations | HRAS | 3265 |
Homo sapiens | Primates | Ras | RAS | famplex_relations | NRAS | 4893 |
Homo sapiens | Primates | Vav1 | VAV1 | ncbigene_symbol | VAV1 | 7409 |
Homo sapiens | Primates | Syk | SYK | ncbigene_symbol | SYK | 6850 |
Homo sapiens | Primates | MEK1 | MEK1 | ncbigene_synonym | MAP2K1 | 5604 |
Homo sapiens | Primates | ERK1 | ERK1 | ncbigene_synonym | MAPK3 | 5595 |
Homo sapiens | Primates | ERK1/2 | ERK2 | ncbigene_synonym | MAPK1 | 5594 |
Homo sapiens | Primates | Rho | RHO | ncbigene_symbol | RHO | 6010 |
Homo sapiens | Primates | Rho | RHO | ncbigene_synonym | RHOD | 29984 |
Homo sapiens | Primates | Rho | RHO | famplex_relations | RHOA | 387 |
Homo sapiens | Primates | Rho | RHO | famplex_relations | RHOB | 388 |
Homo sapiens | Primates | Rho | RHO | famplex_relations | RHOC | 389 |
Homo sapiens | Primates | cdc42 | CDC42 | ncbigene_symbol | CDC42 | 998 |
Homo sapiens | Primates | Rac | RAC | ncbigene_synonym | AKT1 | 207 |
Homo sapiens | Primates | Rac | RAC | famplex_relations | RAC1 | 5879 |
Homo sapiens | Primates | Rac | RAC | famplex_relations | RAC2 | 5880 |
Homo sapiens | Primates | Rac | RAC | famplex_relations | RAC3 | 5881 |
Homo sapiens | Primates | Rac | RAC | famplex_relations | RHOG | 391 |
Word | Match | MeSH | Name | ChEBI |
---|
Disease mentions
Word | Match | MeSH | Name | DOID |
---|---|---|---|---|
Cancer | NA | |||
Noonan syndrome | NA |